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Abstract
Background -: Traditional Chinese Medicine (TCM) has been used for thousands of years to treat or prevent diseases,
including cancer. Good manufacturing practices (GMP) and sophisticated product analysis (PhytomicsQC) to ensure
consistency are now available allowing the assessment of its utility. Polychemical Medicines, like TCM, include chemicals
with distinct tissue-dependent pharmacodynamic properties that result in tissue-specific bioactivity. Determining the
mode of action of these mixtures was previously unsatisfactory; however, information rich RNA microarray technologies
now allow for thorough mechanistic studies of the effects complex mixtures. PHY906 is a long used four herb TCM
formula employed as an adjuvant to relieve the side effects associated with chemotherapy. Animal studies documented
a decrease in global toxicity and an increase in therapeutic effectiveness of chemotherapy when combined with PHY906.
Methods -: Using a systems biology approach, we studied tumor tissue to identify reasons for the enhancement
of the antitumor effect of CPT-11 (CPT-11) by PHY906 in a well-characterized pre-clinical model; the administration
of PHY906 and CPT-11 to female BDF-1 mice bearing subcutaneous Colon 38 tumors.
Results -: We observed that 1) individually PHY906 and CPT-11 induce distinct alterations in tumor, liver and
spleen; 2) PHY906 alone predominantly induces repression of transcription and immune-suppression in tumors; 3)
these effects are reverted in the presence of CPT-11, with prevalent induction of pro-apoptotic and pro-
inflammatory pathways that may favor tumor rejection.
Conclusions -: PHY906 together with CPT-11 triggers unique changes not activated by each one alone suggesting
that the combination creates a unique tissue-specific response.
Background
Although traditional Chinese medicine (TCM) has been
applied for thousands of years in Asia, its recognition by
Western countries rests upon objective documentation
of its value. To date, no systematic evaluation of TCM
has provided conclusive proof of efficacy, though several
studies suggest beneficial applications in certain patient
populations [1]. In cancer patients, TCM has been
applied predominantly to control cancer-associated
symptoms or decrease treatment-related toxicity. How-
ever, it was observed that some herbal products display
anticancer properties [2]. Most TCM products currently
used in cancer therapy display a broad range of biologi-
cal effects including pro-apoptotic activity, inhibition of
angiogenesis and boosting of immune response. For
instance, it was recently observed that a significant pro-
portion of ginseng’s biological activity in vivo is exerted
through modulation of innate immunity [3].
PHY906 is a TCM formulation that has been used for
the last 1,800 years to treat distressing conditions of the
gastrointestinal tract. Several preclinical animal models
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any medium, provided the original work is properly cited.tested the ability of PHY906 to increase the therapeutic
window of chemotherapy by decreasing its gastrointest-
inal side effects. Recently, we documented strong pro-
tective effects by PHY906 on chemotherapy-induced
intestinal toxicity [4,5]. Moreover, pre-clinical and
early-phase clinical trials of PHY906 in combination
with chemotherapy in patients with advanced hepatocel-
lular carcinoma [6], pancreatic cancer and other gastro-
intestinal malignancies [7] have yielded promising
results.
To date, no experimentally-validated hypothesis
about the adjuvant anti-tumor mechanisms of PHY906
given during chemotherapy has been proposed. Exten-
sive biochemical characterization and standardization
of PHY906, which includes a mixture of four herbs:
Glycyrrhiza uralensis Fisch (G), Paeonia lactiflora Pall
(P), Scutelleria baicalensis Georgi (S), and Ziziphus
jujuba Mill (Z) under GMP conditions, using Phy-
tomics technology indicates that the product can be
prepared with a high degree of consistency [8] greatly
improving the interpretability of pre-clinical and clini-
cal results. Chemical and biological characterization of
PHY906 demonstrated that a large number of bioactive
substances are present in the four herbal preparations.
Because of the pharmacokinetic differences in the pro-
cessing and creation of structurally different chemicals,
and the pharmacodynamic differences of new metabo-
lites vs. parent compounds, the biological effects
identified in vitro are difficult to ascribe as a relevant
anti-cancer mechanism in vivo [9]. Moreover, none of
t h eh e r b sd i s p l a ya l o n ein vivo the effectiveness
displayed by their combination. This complexity has
hampered the design of mechanistic studies evaluating
specific biological pathways in the context of the
cumulative effects of PHY906, particularly when its
effects are evaluated in vivo where different active
components have the opportunity to interact with can-
cer and normal host’s cells simultaneously. Therefore,
a first effort toward the understanding of the mechan-
isms of action of PHY906 should frame the overall
effects of the herb in vivo using global transcriptional
profiling. Thus, we scanned alterations of the tran-
scriptional program induced by PHY906 following its
administration as a single agent and in combination
with Irinotecan (CPT-11) in a well-characterized pre-
clinical model in which both agents were administered
to female BDF-1 mice bearing subcutaneous Colon 38
tumor implants. Its effects were compared with those
observable in normal tissues such as autologous liver
and spleen. The study demonstrated that PHY906 or
CPT-11 alone induces significant transcriptional
changes in the tumor and in normal tissues that are
exquisitely tissue-specific. PHY906 significantly ampli-
fies the effects of CPT-11 in the tumor tissue. Most
importantly, PHY906 together with CPT-11 triggers
unique changes not triggered by each one alone and
this may explain the enhanced anti-tumor activity of
the combination.
Materials and methods
Animal Model
Murine Colon 38 cells were transplanted subcutaneously
into four- to six-week-old fe m a l eB D F 1m i c e( C h a r l e s
River Laboratories, Wilmington, MA) as previously
described [4]. After 10 to 14 days, mice with tumor
sizes of 150-300 mm
3 were selected. PHY906 was given
orally over 72 hours (500 mg/kg) while CPT-11 (360
mg/kg) was administered intra-peritoneally on Day 0. In
the combination group, the first dose of PHY906 was
given 30 minutes prior to CPT-11 administration. Mice
(BDF1 bearing Colon 38 tumors) were terminated by
cervical dislocation 72 hours after initiation of drug
treatment. Tumor tissue was removed and divided and
either frozen for total RNA isolation or placed in 10%
neutral buffered formalin for histological analysis. All
animal experiments were carried out in accordance with
an approved Yale University Institutional Animal Care
and Use Committee (IACUC) protocol. Murine Colon
38 cell lines were provided by Dr. Giuseppe Pizzorno,
Ph.D., Pharm.D (Translational Science, Nevada Cancer
Institute, USA).
Gene expression microarray analysis
Total RNA was extracted from mouse tissues using
TRIzol
® (Invitrogen) and 3 μg were amplified by in vitro
transcription [10]. Pooled total RNA from mixed normal
mouse tissues was used as universal reference. Both test
and reference RNA were labeled respectively with Cy5
and Cy3 using ULS aRNA Fluorescent Labeling kit
(Kreatech, Netherlands) and co-hybridized to a 36K
mouse oligonucleotide arrays (Operon, Version 4.0
Mouse Genome Oligo Set containing 35,852 probes
representing approximately 25,000 genes). Hybridization
was carried out overnight at 42°C and the microarray
slides were scanned by GenePix Pro 4.0 (Axon,
Sunnyvale, CA).
Microarray data analysis and statistics
The resulting data files were analyzed using BRBArray
Tools [11]. Raw data were background subtracted. The
complete experimental data set including 111 samples
from mouse tumor, liver and spleen was filtered retain-
ing transcripts with at least 80% spot presence with spot
size requirement >20 μM, and intensity in at least one
channel > 200 and override the other channel to 200 to
avoid high ratio artifact. Intensity ratios above 64 were
truncated. Data were normalized using median normali-
zation across the array. This filter selected 18,549
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subsequent analyses. A high stringency comparison
(significance p-value cutoff < 0.001) was used to identify
transcripts with a high likelihood of differential expres-
sion among experimental groups and a low stringency
gene enrichment (cutoff p-value < 0.05) was used for
pathway analysis. For all experiments, multivariate (glo-
bal) permutation test (pt =1 0 , 0 0 0pts) was applied to
test whether the number of transcripts obtained in each
analysis was above the likelihood expected by chance.
Gene functions were congregated into pathways and
networks using Ingenuity Pathways Analysis (IPA) soft-
ware (v7.6). Canonical pathways enriched in differen-
tially expressed transcripts were ranked according their
significance (-log p value).
Real-Time qPCR
For each sample, 0.5 to 1 ug of total RNA was con-
verted into cDNA using M-MLV reverse transcriptase
according to manufactures instructions using random
primers. All individual primer sets for genes of interest
were designed using NCBI primer design on exons junc-
tion when possible. Primer pairs were then run through
Beacon Designer™ Free qPCR Designer Program http://
www.premierbiosoft.com/jsp/marketing/FreeToolLogin.
jsp?PID=1 to eliminate primer-dimers that may interfere
with assay. Primers were then checked using melt curve
analysis for one product and their efficiency determined
using iCycler software. Real Time PCR was performed
on BioRad-i-Cycler system using Sybr
® green as dye and
Phusion
® DNA Polymerase with the following condi-
tion: 98°C 1 min followed by (98°C :10 sec, 60°C :10 sec
72°C :10 sec) X either 38 or 44 cycles. Sample serial
dilutions served as source for relative standard curve.
Samples (n = 10/group) were run in duplicate. For each
sample, the relative copy number for the gene of interest
is divided by the relative copy number for B-actin. Final
result is presented as relative expression of the gene
relative copy number compared to the mean of the
same gene in PBS control group. Results calculated
using Excel and graphed in GraphPad Prism. Primer
sequences are shown in Additional file 1, Table S1
Immunohistochemistry
Tissues were embedded in OCT, stored in liquid nitro-
gen and cut into 10 μms e c t i o n sa t- 1 8 ° C .T h et i s s u e
sections were fixed in acetone at 4°C for 10 minutes and
stored at -80°C. Upon immunohistochemistry staining,
sections were post-fixed in methanol with 3% acetic acid
for 20 minutes. After two 5 minute washes in PBS, the
sections were bathed for 20 minutes in 3% H2O2 in Tris
Buffered Saline with 0.05% Tween-20 followed by incu-
bation for 1 hour in blocking buffer (Gelatin 0.1%, BSA
1%, Goat serum 10% in TBS). Primary antibody F4/80
(abcam #ab16911 rat monoclonal-BM8) was diluted 1:10
in blocking buffer and incubated with the tissue sections
overnight at 4°C. After washing 4 times in PBS and TBS
at room temperature, rat on mouse HRP-Polymer Kit
(#RT517G, BIOCARE) was incubated with the section
for 20 minutes. After washing, the HRP polymer that
conjugates to the probe was added for 20 minutes
followed by DAB development. Sections were then
counter stained with hematoxylin.
Results
Effect of PHY906 on tumor growth and weight in CPT-11
treated BDF-1 mice bearing colon 38 tumors
Forty BDF-1 mice, each bearing a colon 38 tumor, were
divided into the following four treatment groups:
Phosphate Buffered Saline (PBS, control), PHY906 (500
mg/Kg, twice a day for 72 hours), CPT-11 (Camptosar
®,
360 mg/kg), or = PHY906(500 mg/Kg), followed 30 min-
utes later by a single injection of CPT-11 (360 mg/kg)
with continued twice a day dosing of PHY906 (500 mg/
Kg) for 72 hours. Tumors were measured 72 hours after
treatment (Figure 1a) and then removed. As expected
[6], PHY906 enhanced the anti-tumor activity of CPT-
11 although alone it had no effect on tumor growth.
These early effects resulted in better long term reduc-
tion of tumor growth compared to CPT-11 treatment
alone up to the 14
th day from the beginning of treat-
ment [12]. No differences in animal body weight were
observed between the CPT-11 and the CPT-11 plus
PHY906 groups.
Comparison between the tumor, spleen and liver
Transcriptional patterns observed in the 4 treatment
cohorts were compared among liver, spleen and tumor
samples. In the absence of treatment (PBS cohort), the
transcriptional program of the tumors was remarkably
different from normal liver and spleen. Multiple dimen-
sional scaling (MDS) based on the complete data set,
clearly separated tissues (Figure 1b). Gene enrichment
b a s e do na nu n p a i r e dt test at a low cutoff stringency
(p-value < 0.05) identified 7,856 transcripts differentially
expressed by tumors compared to the two normal tis-
sues combined. Of these genes, 7,348 had an annotated
function and, therefore, could be used for Ingenuity
Pathway Analysis (IPA). A large number of canonical
pathways (104 over a total of 318) were significantly
altered (Fisher’s exact test threshold p2-value < 0.05) in
the tumor microenvironment compared to the normal
tissues. Most affected cellular growth and proliferation,
intra-cellular signaling and cellular stress. Ranking of
pathways according to percentage of genes affected
identified several immune-related canonical pathways
(IL-22, JAK/STAT, IFN, IL-3 and VEGF signaling)
within the top 15 confirming that chronic inflammation
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pathways predominantly associated with the oncogenic
process were enriched with over-expressed transcripts
(cleavage of mRNA, polyamine regulation in colon
cancer, DNA methylation and protein ubiquitination),
canonical pathways associated with immune function
were more balanced in their frequency of up- or down-
regulated genes.
Because of the disparities among the transcriptional
profiles of various tissues, it became obvious that direct
cross comparisons of the effects of treatment among
different tissues would not be informative; rather indir-
ect comparisons could be made by defining the effects
of various treatments in each tissue and subsequently
comparing different tissues. A four way Anova (F test,
cutoff p-value < 0.001) and univariate t tests (cutoff
p-value < 0.001 and < 0.05) were performed among
(between) treatments for the three tissues to obtain a
general estimate of the number of transcripts propor-
tionally affected in each condition (Additional file 2,
Table S2). Both CPT-11 and PHY906 affected a larger
number of genes in the spleen than in the tumor or
liver. In all tissues, differences were observed among
treatment groups and PHY906 treatment alone bore sig-
nificant and independent effects that were statistically
significant by permutation (pt) test. Moreover, PHY906
significantly altered the effects of CPT-11 in all tissues.
There was little overlap among the effects of the 4 treat-
ments on the tumor or other tissues. The patterns that
were dominant in the tumor microenvironment (innate
= PBS
= PHY906
=CPT-11
=CPT-11+PHY906
Tumor
a
b
d
c
Tumor Spleen Liver
a
b
c
d
a
b
c
d
b
= Tumor
= Spleen
= Liver
PBS treated animals
a
c
p = < 0.001 p = < 0.001
d
Figure 1 Effect of PHY906 and/or CPT-11 on tumor, spleen and liver.( a) Effect of PHY906 and/or CPT-11 on tumor size 72 hours after the
initiation of treatment. The p-values refer to unpaired Student t test between groups. (b) Multidimensional scaling (MDS) based on the complete
filtered data set including 18,549 transcripts demonstrating in Euclidian space distances among tumor, liver and spleen of animals treated with
PBS. (c) Unsupervised, self-organizing clustering based on transcripts that passed for each tissue studied a filter requirement of 80% presence
and at least one experiment with a ratio above 4 out of 18,549 that originally passed the less stringent filter (experimental clustering based on
Kendal’s Tau regression model, tumor = 2, 635 transcripts, spleen = 2,079 transcripts, liver = 1,059). (d) Self-organizing clustering based on 700
genes out of 1,132 tumor genes differentially expressed among the four treatment groups (F test, p-value cutoff < 0.001) that passed a filter of
80% presence and a log ratio ≥ 3 in at least one experiment. Highlighted in yellow is the area of the heat map were enhancement of the CPT-
11 effects by the combination CPT-11+PHY906.
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B; NF-kB) were minimally affected in the other two
organs. Thus, as expected, the effects of either PHY906
and/or CPT-11 are highly tissue specific.
Analysis of therapy on the tumor tissues
The effect of PHY906 and CPT-11 on tumor tissues
was analyzed by comparing the transcriptional program
of tumors from mice treated with PBS (n = 10),
PHY906 (n = 9), CPT-11 (n = 10) and CPT-11
+PHY906 (n = 9). Unsupervised clustering demon-
strated preferential grouping of PHY906 treated samples
compared with PBS treated samples (Fisher’s exact test
p2-value < 0.001 between sub-cluster a vs b, Figure 1c)
while a less clear but still significant separation was
observed in tumors from animals treated with CPT-11
+ P H Y 9 0 6c o m p a r e dt oC P T - 1 1a l o n e( F i s h e r ’se x a c t
test p2-value = 0.003 between sub-cluster c vs d).
Furthermore, four tumor samples (one from a mouse
treated with CPT-11 alone and three from mice treated
with the combination) clustered separately from the
other CPT-11 treated animals. A multivariate analysis (F
test) adopting a < 0.001 p-value cutoff identified 1,132
genes (global pt test p-value < 0.001) differentially
expressed among the four groups (Table 1). A self-orga-
nizing clustering algorithm based on these transcripts
confirmed that salient differences were due to the
CPT-11 therapy (Figure 1d). Within each sub-cluster,
however, there was significant separation between treat-
ment groups (Fisher’s exact test p2-value < 0.001 for
PBS vs PHY906 and for CPT-11 vs. CPT-11+PHY906).
Comparison of the CPT-11+PHY906 with the CPT-11
treatment group demonstrated that PHY906 overall
enhanced several transcriptional nodes effected by the
latter (Figure 1d, yellow box).
Effect of PHY906 on tumors
A high stringency Student t test (cutoff p-value < 0.001)
identified 117 genes affected by PHY906 (pt test p-value
< 0.001(Table 1); of which 113 had an annotated
function suitable for IPA. This analysis revealed a
self-organizing network that involved predominantly cell
to cell contact and movement. A less stringent gene
enrichment analysis with a cutoff p-value of < 0.05
yielded 1,759 genes (pt test p-value < 0.001) of which
1,664 had an annotated function. The application of IPA
to this gene set demonstrated that most transcripts were
related to general processes of cellular metabolism, and
the majority were down-regulated (Additional file 3,
Figure. S3a). In addition, several other canonical path-
ways related to immune function appeared affected. We,
therefore, displayed immune-related canonical pathways
side by side comparing their constitutive activation in
the tumor microenvironment (compared to the normal
tissues, Figure 2a) with their alterations in various
treatment groups (Figure 2b-e). PHY906 appeared to
suppress the expression of genes belonging to most
pathways compared to their constitutive expression in
the tumor microenvironment.
Effect of CPT-11 on tumors
Class comparison between tumors from mice treated
with PBS or CPT-11 identified 570 genes differentially
expressed at a Student t-test cut-off p-value of < 0.001
(pt test p-value < 0.001) of which 557 had an annotated
function (Table 1). Congregation of genes into
functional networks identified the NF-kB family, master
regulator of innate immune responses and apoptosis, as
the top target of CPT-11 (score 45, focus molecules 28,
Figure 3). A dichotomy was noted in the expression of
NF-kB-dependent genes with a general down-regulation
of the transcripts associated with innate immune
responses including interferon regulatory factor (IRF)-1
and upregulation of genes regulating apoptosis including
mitochondrial fatty acid oxidation [13]. Overlay of the
effects of PHY906 alone demonstrated that the herbal
extract had no direct effects on this pathway. However,
when PHY906 was given in combination with CPT-11, a
remarkable reversal of the anti-inflammatory effects
induced by CPT-11 was observed. To better illustrate
Table 1 Summary of differentially expressed tumor genes among treatment groups
Tumor Microenvironment Test Number of genes < 0.001 and
(<0.05 total/annotated)*
Pt p-value
for <0.001 cutoff
†
Four way F test 1,132 < 0.001
PBS vs PHY906 t test 117/113 (1,759/1,664) < 0.001
PBS vs CPT-11 t test 570/557 (2,630/2,513) < 0.001
PBS vs CPT-11+PHY906 t test 798/774 (3,347/3,190) < 0.001
CPT-11 vs CPT-11+PHY906 t test 93/91 (1,556/1,477) < 0.001
Number of sample: PBS = 10; PHY906 = 9; CPT-11 = 10; CPT-11 + PHY906 = 9; Total 38
*Cutoff of p-value < 0.05 was used to select genes for IPA; In parentheses are the number of genes identified at <0.05 level and with an annotated function that
could be used for IPA;
†although the pt test p-value is shown for the <0.001 analyses, identical results were obtained for the lower stringency analyses. Details
concerning comparisons among other tissues and treatments are provided in the extended table as an additional file (Additional file 2, Table S2).
Note. Pt test: permutation test
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compared to PBS was performed focusing on the
immune regulatory aspects of the treatments (cutoff <
0.05), which identified 2,630 transcripts (2,513 with
annotated function for IPA, Additional file 3, Figure.
S3b). Compared to the constitutive expression of
immune related networks in the tumor microenviron-
ment (Figure 4a), CPT-11 had an ambivalent effect with
down regulation of several pro-apoptotic/pro-inflamma-
tory transcripts including IRF-1 and, down-stream of it
several interferon stimulated genes (Figure 4c). This is
an important observation because IRF-1 is the master
regulator of the acute inflammatory switch with
powerful pre-inflammatory/pro-apoptotic [14] and anti-
angiogenic properties [15]. Side by side comparison of
immune pathways between PHY906 and CPT-11 treated
animals revealed that the latter had a mixed effect
compared with the immune suppressing effects of the
former (Figure 2c).
Effect on tumors of PHY906 when combined to CPT-11
High stringency class comparison between CPT-11
+PHY906 and PBS treated animals (t test cutoff p-value
< 0.001) identified 798 differentially expressed tran-
scripts. Enrichment analysis (threshold p-value of
< 0.05) identified 3,347 genes (3,190 with an annotated
function) (Table 1). Both data sets suggested that the
combination reversed the down-regulation of the
expression of genes related to innate immune responses
observed with CPT-11 treatment. Comparison of the 15
0.50
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FcJ rec phagocytosis
fMPL sign
GM-CSF sign
HMGB1 sign
IGF1 sign 
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Figure 2 Effect of PHY906 and/or CPT-11 on tumor specific canonical pathway with immunologic function. (a)S t a c k e db a rc h a r t
summarizing the 23 most affected canonical pathways with immunologic function according to IPA based on 7,348 genes with annotated
function differentially expressed (t test cutoff p-value < 0.001) between colon 38 tumors and the combined liver and spleen database in animals
treated with PBS. The same canonical pathways are portrayed looking at the effects on the tumor microenvironment of (b) PHY906, CPT-11 (c)
and CPT-11+PHY906 (d). Finally, differences between CPT-11+PHY906 compared to CPT-11 alone are shown (e).
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mary differences between combination therapy and
CPT-11 alone were quantitative, with more genes
being up regulated by the combined treatment (Addi-
tional file 3, Figure. S3c). Side by side comparison of
immune pathways (Figure 2d) clearly demonstrated
that the combination enhanced the expression of
pro-inflammatory functions. Thus, PHY906 enhanced
the pro-inflammatory effects of the chemotherapy act-
ing in an opposite direction than when given alone
(Figure 2b). Overlay of the PHY906 plus CPT-11
effects (Figure 4d) on the CPT-11 modulated NF-kB
network clearly demonstrated an up regulation of
genes associated with NF-kB immune function includ-
ing the activation of the MyD-88/IRF-5 signaling
network. Moreover, a diminished suppression of IRF-1
was observed with an average ratio going from 0.3
with CPT-11 vs PBS to 0.64 when CPT-11+PHY906
were compared to PBS.
PHY906-specific effects during CPT-11 therapy on tumors
To better understand the specific contribution of
PHY906 when used in combination with CPT-11, we
compared tumor samples from animals treated with
CPT-11 to those treated with CPT-11+PHY906 and
identified 93 genes that were differentially expressed
(pt test p-value < 0.001). Enrichment analysis identified
1,556 genes differentially expressed (pt test p-value
< 0.001, 1,477 annotated) (Table 1). IPA analysis
demonstrated that the overlap in the ranking of most
affected canonical pathways was limited to pro-inflamma-
tory pathways such as IFN, IL-9 and JAK/STAT signaling,
suggesting that the addition of PHY906 to CPT-11 treat-
ment predominantly affected pathways associated with the
immune switch from chronic to acute inflammation
(Additional file 3, Figure. S3d). These effects could be best
appreciated by the side by side comparison (Figure 2e)
where PHY906 proportionally enhanced all immune
regulatory pathways associated with acute inflammatory
processes. The best example was the complete reversal of
the expression of genes associated with IFN signaling with
up-regulation of the IFN-a receptor, JAK1, STAT-2, IRF-1
and IRF-5.
Combining the analysis of CPT-11+PHY906 vs
CPT-11 and CPT-11+PHY906 vs PBS one observes that
there is a striking immunologic effect of PHY906 when
given in combination with CPT-11 that is an activation
of the IRF-5/Myd88 pathways and the reversal of the
suppression of the STAT-1/IRF-1 pathways (Figure 4e).
This preliminary data suggests that PHY906 works in
the context of chemotherapy by enhancing inflammation
through IRF-5 while blocking the anti-apoptotic effects
likely activated by cancer cells through the suppression
of IRF-1 expression [14].
Validation of immune cell infiltration in tumor by
immunohistochemistry
T h ep r e v i o u sa n a l y s i ss u ggested that the colon 38
tumors are characterized by moderate inflammation
compared with normal tissues and that this can be
modulated by the anti-inflammatory effects of PHY906
alone and the pro-inflammatory effects of CPT-11 and
even further by the combination of the two. Thus, we
looked at the presence of macrophages in tumors as a
general marker of the inflammatory process. In parti-
cular we were interested in macrophage infiltration in
the combination treatment in which IRF-5 was found
strongly up regulated. IRF-5 serves an integral role in
the gene induction program activated by Toll-like
receptor signaling [16] while playing a potent role as
mediator of cell cycle arrest and cell death [17].
Among various pro-inflammatory activities, IRF-5
expressed in mice by activated macrophages can
induce the production of several chemokines including
CCL-1/I-309, CCL-2/monocyte chemotactic protein 1
(MCP-1), CCL-4/macrophage inflammatory protein 1 b
(MIP-1b), CCL-5/Regulated upon Activation, Normal
T-cell Expressed, and Secreted (RANTES) and CXCL-
8/IL-8 [18] that can further recruit inflammatory cells
in areas of inflammation. CCL-2/MCP-1 (Figure 5e)
and CCL-5/RANTES were indeed significantly
up-regulated by the combination PHY906+CPT-11
compared to CPT-11 alone. Therefore, to compare the
CPT-11 vs PBS
IPA
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T test cutoff p-value < 0.001
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Figure 3 Immune network predominantly affected by CPT-11
(the analysis performed at high stringency gene selection; t
test p-value cutoff < 0.001).
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by gene expression analysis, we analyzed the presence
of macrophages in histologically prepared whole tumor
cross-sections. As shown in Figure 5, tumors harvested
3 days post treatment had an increase in the number
of F4/80 antibody positive cells in the CPT-11 and
CPT-11+PHY906 treated tumors compared with the
PBS control group indicating extensive macrophage
infiltration. The comparison of CPT-11+PHY906 with
CPT-11 alone revealed a strongly enhanced macro-
phage infiltration corroborating the transcriptional
signatures. In contrast, PHY906 alone treatment
demonstrated reduced macrophage infiltration com-
pared with PBS alone confirming the anti-inflamma-
tory effects of the herb when given alone. Thus,
PHY906 carries opposite effects in the tumor microen-
vironment by reducing inflammation when given alone
but enhancing acute pro-inflammatory processes
within the tumor when given in combination with
CPT-11.
Validation by real-time qPCR of selected transcripts of
relevance to this study
Several transcripts were selected for validation by qPCR
(Figure 6). Although we have previously shown that
qPCR may not necessarily be an optimal validation
method for array data because it lacks endogenous
reference controls and it is based on reference genes
[19], it still provides an approximate corroboration of
the information obtained with one platform. As shown
here, data from array or qPCR in 10 transcripts relevant
to the study and representing distinct behaviors in
distinct treatment groups were compared side by side
demonstrating a high level of comparability; of note is
the behavior of IRF-5 which was confirmed to be
up-regulated particularly in the PHY-906 with CPT-11
combination and IRF-1 which was significantly down-
regulated in expression by CTP-11 (array p2-value =
0.0002 and qPCR p2-value = 0.0035) treatment. This
phenomenon was partially reversed in the presence of
PHY-906.
Tumor vs Liver+Spleen
CPT-11 vs PBS
PHY906 vs PBS IPA
Low stringency  analysis
T test cutoff p-value < 0.05
CPT-11+PHY906 vs PBS
CPT-11+PHY906 vs CPT
a
b
c
d
e
Figure 4 Immune network predominantly affected by the neoplastic process compared to normal tissues (a) and the effect of PHY906
(b), CPT-11 (c), CPT-11+PHY906 (d) or the differential effect of CPT+PHY906 over CPT-11 alone (e) (the analysis performed at low
stringency for gene enrichment; t test p-value cutoff < 0.05).
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It has been suggested that conventional chemotherapy
induces cancer cell elimination not only through direct
cytostatic or cytotoxic mechanisms but also through
modulation of host’s immune cell function [20]. DNA
damage caused by therapies that disrupt cell cycle has
direct immune stimulatory effects. Tumors do not
regress in immune depleted animals treated with doxor-
ubicin given in combination with IL-12 and several
other cytotoxic agents can induce powerful immune
responses against cancer [20]. Although the effects of
chemotherapeutic agents is currently believed to be due
to the induction of cellular damage and subsequent
activation of innate immune responses, no information
is available about the transcriptional signatures within
the tumor microenvironment that could support this
hypothesis. A few experimental models suggest that che-
motherapy acts by inducing the release of cytokines and
chemokines such as CXCL-9/Monokine induced by
IFN-g (MIG), CXCL-10/IFN-g -induced protein 10 kDa
(IP-10), CCL-2/MCP-1, CCL-3/MIP-1a,C C L - 5 /
RANTES, IL-6, IFN-g and TNF [21,22]. This study
assessed the effect of chemotherapy at the global tran-
script level.
The study focused on the early effects of treatment
which are more likely to provide mechanistic informa-
tion about the up-stream events leading to the observed
p h e n o m e n o l o g ya sw eh a v ep r e v i o u s l ys h o w ni np r e c l i -
nical [23] or clinical models [24,25]. The results support
the current view that chemotherapy acts, at least in part,
by modulating immune responses (Figure 2c) resulting
in enhancement of immune infiltrates (Figure 5c). Of
note, CPT-11, modulated the high mobility group box-1
pathway, confirming the central role that it plays in the
induction of anti-cancer activity by chemotherapeutics
through activation of innate immunity [26,27]. The
effects of CPT-11 on immune responses at the dose
used in this study were, however, ambivalent with a
balanced proportion of genes related to inflammatory
processes being up-regulated or down-regulated over
their baseline activation within the tumor microenviron-
ment (Figure 2). CPT-11 effects were centered on the
regulation of apoptosis by NF-kB including activation of
genes related to mitochondrial fatty acid oxidation,
sodium pump regulation such as the ATPase, Na+/K+
transporting, alpha 1 polypeptide (ATP1A1), the tumor
necrosis factor receptor super-family member 12A
(Fn14/TNFRF12A/TWEAKR) inducer of apoptosis, the
tumor necrosis factor AIP3 interacting protein 2
(TNIP2), the inositol 1,4,5-trisphosphate 3-kinase B
(ITPKB). These genes have predominantly pro-apoptotic
effects, while genes with clear anti-apoptotic effects and
related to cell growth such as lactate dehydrogenase A
(LDHA) and the transferrin receptor (TFRC) were
down-regulated; thus, it appears that CPT-11 counter-
acts the anti-apoptotic activity of NF-kB inducing apop-
tosis and alterations of cellular metabolism. In contrast,
pro-inflammatory pathways downstream of NF-kB regu-
lation were predominantly down-regulated at this early
time point perhaps because the tissue damage induced
by chemotherapy had not reached a sufficient intensity
to induce immune activatio n( F i g u r e4 aa n d5 c ) .T h e
complex activation of NF-kB-dependent transcripts lead-
ing to apoptosis and/or inflammation deserves discus-
sion. The anti-apoptotic effects of NF-kBa r eb a l a n c e d
in cancer by the tumor suppressor effects of IRF-1 and/
or IRF-5 which directly inhibit its cyto-protective activ-
ity [14,28,29]. In particular, IRF-5 can sensitize tumors
treated with CPT-11 to DNA damage-induced apoptosis
and cell death [30]. In baseline conditions IRF-5 was
found to be down-regulated in Colon 38 tumors com-
pared to normal tissues while the expression of IRF-1
was neutral compared with other tissues (Figure 2a). We
speculate that CPT-11 activates pro-apoptotic pathways
by suppressing IRF-1 expression (Figure 5c) while
leaving unaltered the constitutive down-regulation of
IRF-5 in these tumors. The combined down-regulation
of the two tumor suppressor genes may allow NF-kB to
partially counteract apoptosis while the acute inflamma-
tory process fostering cancer rejection is hampered by
the down-regulation of the IRFs [31].
PHY906 was originally used to treat gastrointestinal
symptoms including those related to the toxic effects of
D. CPT-11+PHY906 
B. PHY906
C. CPT-11
Figure 9.
A.
A. PBS (control)
E.
PBS PHY906 CPT-11 CPT-11
PHY906
CPT-11 vs  PBS . 01
. 04
P Value
CPT-11
PHY906
vs CPT
Figure 5 Macrophage infiltration signatures in tumors treated
with PHY906 and/or CPT-11. Macrophage infiltration in colon 38
tumors treated with PBS (a), CPT-11 (b), PHY906 (c) or Ininotecan
+PHY906 (d). MCP-1 RNA alteration in tumors induced by various
treatments (e)
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Page 9 of 13Figure 6 Quantitative PCR validation of selected genes relevant to the study that were identified as differentially expressed according
to transcriptional analysis among different treatment groups. For each transcript, the first graph shows RNA array results followed by qPCR
validation results. The Y-axis of the Array data graphs shows relative expression ratio of specific gene in samples relative to the mean of the
same gene across PBS control group (REA-Relative Expression in Array). For qPCR validation, the data shown are of the relative expression (RE) of
a gene of interest per actin molecule in sample compared to the averaged ratio of the gene of interest to actin for the entire control group (Y-
axis). Statistics were Student t-tests (two tailed) performed by GraphaPad software. Error bars represent SD. The four graph bars on the X-axis for
each graph represent the different treatment groups.
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Page 10 of 13chemotherapy. Work from our group [4] demonstrates
that PHY906 can revert intestinal damage caused by
CPT-11 through the anti-inflammatory properties of the
herb and the repopulation of intestinal progenitor cells.
This study, did not address the complex effects that
PHY906 has on the gut that will be addressed in the
future, but focused on the early transcriptional changes
observable at the tumor site. To address whether the
effects of PHY906 were tissue specific, we compared the
transcriptional changes at the tumor site with those in
two normal organs characterized by high metabolic
activity (liver) or immunologic functions (spleen). These
organs were also exposed to systemic concentrations of
orally administered PHY906 and/or CPT-11 (i.p.) differ-
ent from those experienced by the front line exposure
in the gut. Comparisons of the transcriptional profiles of
the three tissues demonstrated clear baseline differences
independent of any treatment which made cross com-
parisons of the various treatment effects among various
tissues uninformative. Nevertheless, this approach
clearly demonstrated that the effect of PHY906 and of
chemotherapy with CPT-11 is exquisitely tissue-specific
with very little overlap of pathways regulated by the
various combinations in different tissues. This is not
surprising since each tissue is enriched with different
potential target cells that may react differently to CPT-
11 or PHY906.
While tissues were not micro-dissected or single cell
preparations were not obtained ex vivo,ag e n e r a l
overview of the global changes induced by PHY906
could be obtained. In particular, we were interested in
understanding how a herbal product with supposed
anti-inflammatory properties could paradoxically
increase the anti-tumor effects induced by chemother-
apy; this concept is opposed to the current hypothesis
of how the host immune system cooperates with the
effects of chemotherapy [20]. Besides its immune modu-
latory effects on inflammation, PHY906 could have a
direct impact on cancer cell survival by modulating
apoptosis, autophagy or necrosis in cells undergoing
exposure to chemotherapy. Although we have previously
observed that PHY906 could inhibit tumor cell growth
in culture (Additional file 4, Data in S4), the in vitro
data could be misleading since not all the chemicals in
PHY906 are necessarily absorbed into circulation and
some that are absorbed will be metabolized in vivo.
However, it is possible that some of the in vitro effects
mediated by PHY906 on cancer cells may be retained.
In vivo, PHY906 induced a predominantly downward
modulation of transcription and down-regulation of the
pro-inflammatory activity naturally present within the
tumor. This anti-inflammatory effect was corroborated
by the decreased amount of tissue macrophages seen by
immunohistochemistry (Figure 5b).This is in line with
its postulated functions in the gut [4]. Since no tumor
regression was seen in response to PHY906 adminis-
tered alone, it is unlikely that these effects have relevant
bearing on tumor regression.
The surprising finding of this study emerged when we
examined the effects of the combination of PHY906
plus CPT-11. Contrary to the anti-inflammatory proper-
ties observed when administered alone, PHY906 strongly
counteracted the CPT-11 induced depression of inflam-
mation through the IRF-mediated pathways. In particu-
lar, PHY906 counteracted the down-regulation of the
master regulator of the pro-inflammatory switch and
apoptosis IRF-1 [14,31,32]. Additionally, PHY906
enhanced the expression of IRF-5, another potent pro-
inflammatory transcription factor associated with
immune-mediated, tissue-specific rejection [33-36] as
well as induction of apoptosis of CPT-11 treated cancers
[30]. Thus, we speculate that PHY906, in line with other
experimental models [20], enhances the anti-tumor
properties of chemotherapy with CPT-11 by imparting a
pro-inflammatory state that is not observed in the same
CPT-11 naïve cancerous tissue. The reasons for the con-
tradictory behavior remain to be ascertained, although it
is likely that they involve a modulation of the balance
between the anti-apoptotic and pro-inflammatory func-
tions of NF-kB while, at the same time, inducing the
expression of interferon stimulated genes with chemo-
attractant properties such as CCL-2/MCP-1 and CCL-5/
RANTES [29].
Conclusions
In summary, this is the first study of the effects of a
traditional Chinese compound PHY906 on tumors
undergoing chemotherapy with CPT-11. The results
demonstrated that 1) PHY906 and CPT-11 alone induce
significant alterations in all tissues evaluated (tumor, liver
and spleen); 2) PHY906 and CPT-11 alone generally
induce repression of transcription in the tumors; 3) the
effects of PHY906 are reverted in the presence of a che-
motherapeutic agent such as CPT-11, with a high preva-
lence of transcripts being up-regulated; 4) PHY906 bears
a general immune-suppressive effect in tumors when
g i v e na l o n eb u t ,w h e ng i v e ni nc o m b i n a t i o n ,i tr e s u l t si n
a relative pro-inflammatory pro-apoptotic effect; 5) the
pro-inflammatory, pro-apoptotic effects of PHY906 when
given in combination are exquisitely tumor-specific as
they are not observed in the gut as we recently described
[4] nor in other normal tissues such as liver or spleen as
observed in this study. It should be emphasized that this
striking dichotomy in the behavior of this herbal product
suggest its usefulness to enhance the therapeutic window
for chemotherapeutics as it can decrease toxicity in nor-
mal tissues while at the same time promoting cell death
within the tumor microenvironment.
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Additional file 1: Table S1. qPCR mouse primers used.
Additional file 2: Table S2. Summary of differentially expressed genes
among treatment groups in different tissues.
Additional file 3: Figure S3. Stacked bar chart summarizing the 15
most affected canonical pathways according to IPA based on genes with
annotated function differentially expressed (t-test cutoff p-value < 0.05,
pt test p-value < 0.001) in tumor biopsies between PBS control group
and the treatment groups: (a) PHY906 (b) CPT-11 (c) PHY906+CPT-11.
Finally, differences between PHY906+CPT-11 compared to CPT-11 alone
are shown in (d).
Additional file 4: Data S4. Cytotoxicity of PHY906 on HepG2 after three
days exposure.
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